Clinical trial
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00318422 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00318422 |
|---|---|
| Title | Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes |
| Official title | Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subjects With Type 2 Diabetes. |
| Acronym | LEAD-1 |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | liraglutide, rosiglitazone, glimepiride |
| Enrollment | 1,041 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Apr 26, 2006 |
| Last update posted | Jan 25, 2017 |
| Countries | Argentina, Australia, Brazil, Bulgaria, Croatia, Czechia, Finland, France, Greece, India, Israel, Italy and 11 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: